Alkermes Reveals PhII Success With Antidepressant in Blockbuster CNS Plan

Published April 19, 2013

Alkermes reveals PhII success with antidepressant in blockbuster CNS plan

Filed under: drug treatment programs in massachusetts

Alkermes ($ ALKS) has a shot at offering a new option for treating depression in patients who don't respond to existing drugs. … treated with ALKS 5461 in this study were clinically meaningful and among the most robust I have seen in a phase 2 study …
Read more on FierceBiotech

Sage Therapeutics Shifts Gears, Focuses on Rare Form of Epilepsy

Filed under: drug treatment programs in massachusetts

Of course, when you're a biotech like Cambridge, MA-based Sage Therapeutics, it doesn't hurt to have the backing of a life sciences company creation specialist Third Rock Ventures to get there either. … These drugs were being designed to either …
Read more on Xconomy